The check is in the mail
Executive Summary
Schering-Plough's late user fee payments for the cholesterol absorption inhibitor Zetia (ezetimibe) led to delay in NDA submission date for Merck's Arcoxia. The payments were due Dec. 13, but FDA did not receive payment until Jan. 13. Schering and Merck have a joint venture agreement for Zetia and the fixed-dosed Zetia/Zocor combination...